Richard Wooster, Ph.D., has been appointed chief scientific officer at Blend Therapeutics. Dr. Wooster will be responsible for leading the company’s R&D strategy and clinical operations for lead drug candidates focused on oncology.
Prior to joining the company, Dr. Wooster was vice president and head of the Cancer Metabolism Discovery Performance Unit in Oncology at GlaxoSmithKline, where he led the evaluation of the metabolic pathways that are deregulated in cancer. He previously led the translational medicine group in Oncology at GSK and worked on Tykerb, Mekinist and Tafinlar. During his academic career he discovered the breast cancer susceptibility gene BRCA2, and was one of the founders of the Cancer Genome Project at the Wellcome Trust Sanger Institute.
"We are extremely pleased that Richard has joined our team to lead the discovery and development of Blend's innovative drug candidates, which in the near term are focused on the treatment of cancer, an area of Richard’s core expertise," said Mark Iwicki, Blend’s president and chief executive officer. "His extensive leadership, strategic and technical experience at the highest levels in cancer genetics and pharmaceutical drug discovery and development will be a great asset to the company to drive innovation and our partnering activities. Richard’s impact from the discovery of mutations in BRCA2 and BRAF, passion to develop personalized medicines, and innovation in drug discovery align perfectly with Blend’s objectives.”